Analyzing Nemaura Medical (NASDAQ:NMRD) and Daxor (NASDAQ:DXR)

Nemaura Medical (NASDAQ:NMRD) and Daxor (NASDAQ:DXR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, profitability, risk and analyst recommendations.

Profitability

This table compares Nemaura Medical and Daxor’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nemaura Medical	N/A	N/A	N/A
Daxor	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent recommendations and price targets for Nemaura Medical and Daxor, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nemaura Medical	0	0	0	0	0.00
Daxor	0	0	1	0	3.00

Daxor has a consensus price target of $24.75, indicating a potential upside of 217.31%. Given Daxor’s stronger consensus rating and higher possible upside, analysts plainly believe Daxor is more favorable than Nemaura Medical.

Valuation & Earnings

This table compares Nemaura Medical and Daxor”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nemaura Medical	$3,017.00	1.34	-$14.14 million	($0.39)	0.00
Daxor	$2.61 million	14.48	N/A	N/A	N/A

Daxor has higher revenue and earnings than Nemaura Medical.

Institutional & Insider Ownership

4.4% of Nemaura Medical shares are owned by institutional investors. Comparatively, 1.3% of Daxor shares are owned by institutional investors. 40.4% of Nemaura Medical shares are owned by insiders. Comparatively, 59.0% of Daxor shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Nemaura Medical has a beta of 0.27, meaning that its share price is 73% less volatile than the S&P 500. Comparatively, Daxor has a beta of -0.46, meaning that its share price is 146% less volatile than the S&P 500.

Summary

Daxor beats Nemaura Medical on 6 of the 8 factors compared between the two stocks.

About Nemaura Medical

Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.

About Daxor

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.